Adult Clinical Trials

Lymphomas - Non-Hodgkin's lymphoma and Hodgkin's disease

If you need additional information about any of the trials listed or would like to inquire about other open trials, please contact Lymphoma Clinical Trials Office at 919.681.4769.

4 trials identified.

A randomized, open-label phase 2 study of denintuzumab mafodotin (SGN-CD19A) plus rituximab, ifosfamide, carboplatin, and etoposide (19A+RICE) chemotherapy vs. RICE in the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are candidates for autologous stem cell transplant
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Matthew McKinney
Contact: LYMPHOMA CLINICAL TRIALS OFFICE
Phone: 919.681.4769
Reference Number: 00066502
View this trial at ClinicalTrials.gov

A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination with Tremelimumab or AZD9150 in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: David Rizzieri
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.681.4769
Reference Number: 00073198
View this trial at ClinicalTrials.gov

PHASE 1 STUDY OF ACTR087, AUTOLOGOUS T LYMPHOCYTES EXPRESSING ANTIBODY COUPLED T-CELL RECEPTORS (CD16V-41BB-CD3), IN COMBINATION WITH RITUXIMAB, IN SUBJECTS WITH RELAPSED OR REFRACTORY CD20-POSITIVE B-CELL LYMPHOMA
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Matthew McKinney
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.681.4769
Reference Number: 00073532
View this trial at ClinicalTrials.gov

Alliance A051301: A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Phase: Phase III
Sponsor: Cooperative Group Initiated
Principal Investigator: Jeffrey Crawford
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.681.4769
Reference Number: 00078528
View this trial at ClinicalTrials.gov